Breezula Phase III 12-Month Data Released by Cosmo Pharma Research/Science 4/15/2026
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
View this post in the Community →
Similar Community Posts Join
6 / 238 resultscommunity Clascoterone and Dutasteride for Stabilization
The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.
community Question about clascoterone acne cream
Clascoterone cream can be used on the scalp, but it may not be effective due to its dosage. AR antagonists like clascoterone are generally less effective than 5AR inhibitors for hair loss.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
community Clascoterone/ Breezula will it work
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
community Clascoterone powder already available?
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
community Clascoterone vs RU58841? What’s more effective?
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
Related Research
6 / 98 resultsresearch Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.
research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
Clascoterone 1% cream is a promising new treatment for acne.
research Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
Clascoterone may be an effective topical treatment for hair loss.